Establishment of lung cancer patient-derived xenograft models and primary cell lines for lung cancer study

被引:19
|
作者
Jiang, Yanan [1 ,2 ]
Zhao, Jimin [1 ,2 ]
Zhang, Yi [3 ]
Li, Ke [1 ]
Li, Tiepeng [5 ]
Chen, Xinhuan [1 ,2 ]
Zhao, Simin [1 ]
Zhao, Song [3 ]
Liu, Kangdong [1 ,2 ,4 ]
Dong, Ziming [1 ,2 ]
机构
[1] Zhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou 450001, Henan, Peoples R China
[2] Henan Prov Cooperat Innovat Ctr Canc Chemoprevent, Zhengzhou 450001, Henan, Peoples R China
[3] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China
[4] China US Henan Hormel Canc Inst, Zhengzhou 450008, Henan, Peoples R China
[5] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou 450008, Henan, Peoples R China
关键词
Lung cancer; Patient-derived xenograft; Signal pathway; Primary cell culture; IN-VIVO MODELS; MUTATIONS; EVOLUTION; THERAPY; PATHWAY; EGFR;
D O I
10.1186/s12967-018-1516-5
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: The overall 5-year survival rate of lung cancer is about 15% even with therapeutic drugs like tyrosine kinase inhibitors. Ideal models are urgently needed for exploring mechanisms and finding new drugs. Patient-derived xenografts (PDX) models and primary cells are both used to screen therapeutic regimens for cancer. However, PDX models and primary cells from the same patient are difficult to establish. Their consistency to the original tumor tissue is not well studied. Methods: 31 lung cancer patient tissues were procured to establish the lung cancer PDX models and primary cell lines. Tumor growth measurements, histological and immunohistochemistry analysis, Western blotting, EGFR and K-RAS mutation detection and gefitinib sensitive assay were performed to evaluate the characteristic of established PDX models. Immunofluorescence analysis, anchorage-independent cell growth, Western blotting and gefitinib sensitive assay were performed to assay the characteristic of established primary cell lines. The whole-exome sequencing was used to compare the characteristic of the patient's tumor tissue, established PDX and primary cell line. Results: Twenty-one lung cancer PDX models (67.74%, 21/31) and ten primary cell lines (32.25%, 10/31) were established from patients' tumor tissues. The histology and pathological immunohistochemistry of PDX xenografts are consistent with the patients' tumor samples. Various signal pathways were activated in different PDX models (n = 5) and primary cell lines (n = 2). EGFR mutation PDX model and primary cell line (LG1) were sensitive to gefitinib treatment. The expression of CK8/18, TTF1 and NapsinA in LG1 and LG50 primary cells were also positive. And the activated signal pathways were activated in LG1 and LG50 primary cell lines. Furthermore, the gene mutation in PDX tumor tissues and primary cell line (LG50) was consistent with the mutation in LG50 patient's tumor tissues. Conclusion: These data suggested that established lung cancer PDX models and primary cell lines reserved mostly molecular characteristics of primary lung cancer and could provide a new tool to further understand the mechanisms and explore new therapeutic strategies.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Establishment of lung cancer patient-derived xenograft models and primary cell lines for lung cancer study
    Yanan Jiang
    Jimin Zhao
    Yi Zhang
    Ke Li
    Tiepeng Li
    Xinhuan Chen
    Simin Zhao
    Song Zhao
    Kangdong Liu
    Ziming Dong
    [J]. Journal of Translational Medicine, 16
  • [2] Establishment of Gastric Cancer Patient-derived Xenograft Models and Primary Cell Lines
    Lu, Jia-huan
    Wang, Yun
    Meng, Qi
    Zeng, Zhao-lei
    [J]. JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2019, (149):
  • [3] Establishment and molecular profiling of patient-derived xenograft models of Korean patients with primary lung cancer
    Kim, Tae Ho
    Heo, Hyunjin
    Lee, Soo Jung
    Lee, Seungje
    Hwang, Eunjoo
    Lee, Jinseon
    Lee, Heekyoung
    Koo, Kevin
    Lee, Hanna
    Lee, Seungjae
    Rhee, Hwanseok
    Lee, Jong Eun
    Kim, Jhingook
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [4] ESTABLISHMENT OF PRIMARY PATIENT-DERIVED CANCER CELLS OF LUNG CANCER
    Lin, Chih-An
    Yu, Chong-Jen
    Yang, Pan-Chyr
    Ho, Chao-Chi
    [J]. RESPIROLOGY, 2018, 23 : 287 - 287
  • [5] Patient-derived Xenograft Models of Small Cell Lung Cancer for Therapeutic Development
    Vidhyasagar, V.
    Ul Haq, S.
    Lok, B. H.
    [J]. CLINICAL ONCOLOGY, 2020, 32 (10) : 619 - 625
  • [6] Patient-derived cell line, xenograft and organoid models in lung cancer therapy
    Huo, Ku-Geng
    D'Arcangelo, Elisa
    Tsao, Ming-Sound
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (05) : 2214 - 2232
  • [7] Genomic and Functional Characterization of Patient-Derived Xenograft Models of Small Cell Lung Cancer
    Farago, Anna
    [J]. ONCOLOGIST, 2017, 22 : S3 - S3
  • [8] Establishment of patient-derived xenograft (PDX) models for small cell lung cancer (SCLC) as a preclinical platform for drug development
    Carlson, Patrick
    Ricono, Jill
    Mullins, Chelsea
    Broudy, Thomas
    Mirsaidi, Cyrus
    Nair, Praveen
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [9] Genomic evolution of non-small cell lung cancer during the establishment and propagation of patient-derived xenograft models
    Hynds, R.
    Huebner, A.
    Pearce, D.
    Pich, O.
    Akarca, A.
    Moore, D.
    Ward, S.
    Hill, M.
    Jamal-Hanjani, M.
    Marafioti, T.
    McGranahan, N.
    Swanton, C.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (08) : S1384 - S1384
  • [10] Establishment and histopathological study of patient-derived xenograft models and primary cell lines of epithelioid malignant peritoneal mesothelioma
    Yang, Zhi-Ran
    Chen, Zhi-Gao
    Ji, Zhong-He
    Lin, Yu-Lin
    Zhang, Jue
    Ma, Ru
    Li, Zhao
    Jiang, Xi
    Chen, Qian
    Du, Xue-Mei
    Li, Yan
    [J]. EXPERIMENTAL ANIMALS, 2021, 70 (02) : 225 - 235